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Abstract 
Research has demonstrated that the patients’ diagnosis-treatment cycles often significantly deviate from the standardized 
clinical pathways. Analyzing these deviations might result in the further enhancement of the quality of care, the promotion 
of patient safety, an increase in patient satisfaction and an optimization of the use of resources. Understanding pathway 
behavior and deviations becomes possible because of an increased availability of reliable data, which originates from the 
hospitals information systems. 
In this paper we propose a clinical pathway analysis method for extracting valuable medical and organizational 
information on past diagnosis-treatment cycles that can be attributed to a specific clinical pathway. The method is applied 
on the clinical pathway processes in a Gynecologic Oncology Department. 
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1. Introduction 
Clinical pathways represent prescriptive models of the standard healthcare procedures that need to be 
undertaken for a specific patient population [1]. Instances of the clinical pathways (also known as cases) 
describe the actual diagnostic-therapeutic cycle of an individual patient. Typically real-life clinical pathways 
are characterized by the following unique set of properties: 
• High flexibility. Patients most often do not come with the exact same mix of medical conditions (e.g. 
heart conditions, pregnancy, allergies, etc.) [2]. Additionally, medical experts have to deal with 
uncertainty during the treatment, e.g. unexpected outcomes such as adverse drug reactions, drug 
allergies, heart failure or other complications.  
• Complex decision making. While the medical knowledge used in the decision process comes partially 
from published research contributions and widespread medical guidelines (with various kinds of 
evidence levels), it is generally accepted that the decision process is profoundly influenced by the 
expertise and experiences of the involved medical experts. High levels of autonomy are commonly 
awarded to the experts, which results in a high responsiveness in critical situations [3].  
• Network of specialists. While a horizontal job specialization allows those experts to acquire a deep 
knowledge within a specific medical discipline, it often renders it impossible for an expert to execute 
every activity in a clinical pathway. Consequently, clinical pathways are predominantly performed by 
a network of collaborating medical specialists, all with high levels of autonomy to decide on their 
working procedures [4]. Clinical pathways enable the coordination between medical experts and their 
specific activities.  
• High information needs. Within clinical pathways there exist high information requirements both in 
terms of accuracy and availability. Patient specific and situational information are crucial for the 
decision making processes of the individual medical experts. Consequently, a large variety and amount 
of the patient specific information must be exchanged between actors both within a pathway instance 
and between different pathway instances [5]. As a patient can be involved in multiple pathway types, 
inter-pathway information exchanges may take place between pathways of different types.  
• Continuous evolution. A strong academic background, experience-based insights and technological 
developments as well as economic and governmental pressures, contribute to an often implicit but 
continuous evolution of the medical practices and the related clinical pathways [6].  
Medical informatics and decision making researchers have embraced the concept of clinical pathways and 
have used these pathways for configuring a wide spectrum of healthcare information systems, e.g. in [7-13]. 
The main objective of this approach has been the enhancement of the quality of care by improving risk-
adjusted patient outcomes, promoting patient safety, increasing patient satisfaction and optimizing the use of 
resources [14,15].  
In reality, the care processes of individual patients deviate from the standardized path in order to 
accommodate requirements dictated by the patient’s specific medical conditions or the local conditions of the 
healthcare organization [16,17]. This study presents a novel approach that is based on process mining 
techniques to acquire insight in the real sequence of healthcare activities performed on specific patients. 
Additionally, the study reports on the results of a case study in a Gynecologic Oncology department. 
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2. Methods 
2.1. Subjects and Data Source 
The study has been executed on the care processes of 1143 patients of the Gynecologic Oncology 
department of the a major European academic hospital. This data has been made available in the context of 
the Business Process Intelligence Challenge † , for which we obtained an award for most the complete 
analysis. All diagnosis and treatment activities that were performed for these patients during a period of 3 
years, from January 2005 to January 2008 were collected. The selected patients were all diagnosed with a 
cancer pertaining either to the cervix, the vulva, the uterus or the ovaries. In total 236 treatment combinations 
are covered by this set of patients. Different patient subsets were retrieved for examining both radiotherapy 
and chemotherapy cancer treatment.  
A myriad of information has been recorded for each individual activity including the patient identifier, the 
activity type, the timestamp, the performer’s department indicators and information on both the diagnosis and 
treatment type. Exactly 150,291 activities or an average of 131.5 activities per patient (spread: 1-1806 
activities per patient) were recorded. All activity types (677 in total) are fine-grained and directly related to 
diagnostic and therapeutic activities of the gynecologic oncology pathways on which the core processes are 
based. We filtered out all administrative related activities, such as ‘order rate’ (translation of the activity 
‘ordertarief’). An example extract of the data set can be found in Table 1. 
 
 
Table 1: Activity log extract 
2.2. Clinical Pathway Analysis Method 
In this section we introduce the three broad application areas for process mining techniques in a healthcare 
setting: analyzing recurring patterns, pathway variants and exceptional/adverse events (see Figure 1). 
Discovering recurring patterns. Highly specialized medical experts are often confronted with ‘similar’ 
instances of this cause-effects-solutions relation, as a consequence they might unconsciously develop 
optimizations of the clinical pathways. Process discovery and visualization techniques summarize full and 
precise insights on the clinical pathways reality in one visual. Process discovery techniques, such as the 




 Hospital log, TU Eindhoven. http://dx.doi.org/10.4121/uuid:d9769f3d-0ab0-4fb8-803b-0d1120ffcf54 
Patient Event type Treat. Dep. Diagnosis Time
155 follow-up polyclinic consultation 61 SGNA gyn. tumors 1-Jan-05
156 cytological examination vagina 61 LVPT gyn. tumors 1-Jan-05
156 histological examination 61 LVPT gyn. tumors 1-Jan-05
275 teletherapy 13 RATH gyn. tumors 1-Jan-05
275 follow-up polyclinic consultation 13 SGNA gyn. tumors 1-Jan-05
336 potassium flame photometry 603 CHE2 malign cervix 1-Jan-05
336 differential count 603 HAEM malign cervix 1-Jan-05
336 determination trombocyte level 603 HAEM malign cervix 1-Jan-05
336 count of leukocytes 603 HAEM malign cervix 1-Jan-05
10 count of leukocytes 113 HAEM malign cervix 4-Jan-05
10 determination trombocyte level 113 HAEM malign cervix 4-Jan-05
72 differential count 3101 HAEM malign ovary 16-Jan-05
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Analyzing and characterizing pathway variants. The medical condition of patients is determined by a 
broad set of characteristics/factors, e.g. type and location of the tumor, age of the patient, pregnancy, allergic 
reactions, etc. By comparing the specific medical conditions of patients with the factors used for 
characterizing the different clinical pathway variants, the medical expert can identify the best therapeutic 
option. Different approaches can be used for identifying new clinical pathway variants. Firstly, the analyst 
could perform a correlation analysis on the factors, which are usually hidden in the data perspective. After the 
uncovering of important factor correlations, traces can be filtered and the common process characteristics for 
this process variant can be documented. Secondly, a trace clustering technique can be used to cluster pathway 
traces (i.e. a form of unsupervised learning), followed by an analysis of the factors in each cluster [19]. 
Finally, an expert can propose interesting factor combinations (e.g. combination of treatment & diagnosis 
code). 
Identifying and analyzing exceptional medical cases and/or adverse medical events. Two broad sets of 
techniques are of main interest for uncovering both exceptional cases and adverse events: detecting 
inconsistencies between a designed prescriptive model and the real-life process (i.e. conformance checking 
[20]) and verification of specific process properties (i.e. rule-based property verification techniques [21]). 
 
 
Figure 1: Clinical Pathway Analysis Architecture 
3. Results 
3.1. Clinical Pathway Discovery: Recurrent Patterns in Radiotherapy-Based Ovarian Cancer Treatment 
Figure 2 depicts the retrieved care process model of the activities performed by the radiotherapy 
department. This process model consists of three clearly distinguishable blocks: (1) the medical consults, (2) 
the preparatory activities – i.e. the “simulation” activity and the “treatment time” calculation activity – and (3) 
the radiotherapy activities themselves: teletherapy, hyperthermia therapy and brachytherapy.  
The heuristics miner [18] with standard parameterization has been used for the construction of this care 
process model. Models obtained with the heuristics miner typically represent general behavior, as it uses 
frequency thresholds for the selection of the discovered activity ordering relations that will be depicted. The 
numbers on the arcs (representing individual activity sequences) in the process model indicate respectively the 
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frequency- and counterevidence- based level of certainty of the existence of that activity sequence relationship 
(between 0 and 1) and the number of times that sequence between the activities has taken place.  
 
Figure 2: Recurrent patterns in radiotherapy-based ovarian cancer treatment 
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3.2. Exceptional Medical Events: Deviations from the Common Radiotherapy Activity Sequence 
In this section we further investigate the common treatment sequence – teletherapy, hyperthermia therapy 
and brachytherapy – that has been suggested in the retrieved care process model. 
Of the 215 care process instances containing at least one radiotherapy treatment, 190 instances (89%) start 
with teletherapy. Hyperthermia only occurs in a minority, 22 cases or approximately 10%, of the care process 
instances. Extensive testing of these 22 cases revealed that in approximately 27% the hyperthermia therapy is 
followed by an additional teletherapy treatment. In general, we conclude that teletherapy and hyperthermia are 
coupled and that teletherapy precedes hyperthermia. In 144 pathway instances the brachytherapy occurs at the 
end of the care process. In 83% of the cases including brachytherapy, the brachytherapy occurs directly after 
the teletherapy. Approximately 93% of the cases that include hyperthermia end with brachytherapy.  
The adherence to this treatment sequence has been assessed with the LTL-checker tool [21]. LTL-checker 
allows for testing the activity log against (un)expected/(un)desirable process properties that are specified in 
temporal logic.  
3.3. Variance in Paclitaxel-Chemotherapy-Based Treatment 
In this section, we summarize the key observations on the use of Paclitaxel for ovarian cancer over the 
different stages. The ovarian cancer disease stage has a significant influence on the recommended 
chemotherapy [22], and thus results in different variants of the care flow. Visualizations of the variants similar 
to the one provided in Figure 2 can be obtained but were left out due to space restrictions.  
Ovarian Cancer Stage Ia. In [23] it is concluded that patients diagnosed with ovarian cancer stage Ia do 
not require postoperative chemotherapy based on the active ingredient paclitaxel. Accordingly, the three 
patients (patient 1049, 1067 and 1139) diagnosed with stage Ia ovarian cancer did not receive this type of 
chemotherapy. However, we only found activities performed by the operating room in the care path of patient 
1049.  
Ovarian Cancer Stage Ic and II. Further postoperative chemotherapy is recommended for patients with 
ovarian cancer stage Ic or stage II [24]. However, out of the five patients with this medical condition, only 
three have undergone surgery (patient 819, 987,1020). But none of them received a postoperative paclitaxel 
treatment of at least three cycles, as described in [25].  
Ovarian Cancer Stage III. In their literature review Herzog and Herrin [22] list three standard (after 
surgery) chemotherapy courses for stage III ovarian cancer. Each of these courses covers six 21-day-cycle 
treatments based on a combination of paclitaxel with carboplatin or cisplatin. While the majority of the 
paclitaxel administration schedules start with three 21-day-cycles, only the schedule for patient 829 comes 
close to the six 21-day cycle treatment. Based on the activity log we were unable to conclude that any patient 
received the combination of paclitaxel and carboplatin or cisplatin.  
  
AC-Paclitaxel Chemotherapy. Several sources also indicated the benefits of the sequential use of AC (i.e. 
doxorubicin and cyclophosphamide) and Paclitaxel, both in terms of chances for disease-free survival and for 
overall survival (e.g. [10,26]). However, we were unable to find any patient who receives both the AC and 
Paclitaxel therapy. A minority of the patients received a combination of Paclitaxcel and Doxorubicin 
(indicated as ‘doxorubicine liposomal –caelyx’ in the event log).  
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4. Discussion 
4.1. Radiotherapy for Ovarian Cancer 
Based on the retrieved care process model for the radiotherapy department we were able to uncover 
different types of rather exceptional behavior. Firstly, this care process model indicates that a high level of the 
patients in this workflow never receive a radiotherapy treatment, i.e. transitions between a consultation related 
activity and the end state.  
Secondly, under extremely exceptional circumstances, only 4 times according to the event log, a simulation 
activity has been explicitly performed. As a simulation is crucial and the non-execution of this type of activity 
could result in major quality risks, we assume that the registration of this activity has not been done 
systematically or that it is contained in the “treatment time” determination activity.  
Thirdly, while we established a clear sequence between the treatment activities, several patients were 
treated in a different way. For example, multiple patients diagnosed with cancer pertaining the cervix that 
received radiotherapy treatment (indicated by the presence of teletherapy), did not receive brachytherapy (e.g. 
patients 447, 451 and 457). However, according to Gerbaulet et al. brachytherapy is a standard of care for 
cervical cancer [27]. Many plausible explanations may exist, such as the patient’s decision to stop the cancer 
treatment or the performance of the brachytherapy at a different hospital.  
4.2. Chemotherapy for Ovarian Cancer 
Two major deviations from medical guidelines were uncovered during the analysis of the administration of 
paclitaxel-based chemotherapy: the lack of combining platinum agents with paclitaxel and the lack of a 
postoperative paclitaxel-based chemotherapy (and of the surgery itself). 
Secondly, gynecologic oncology research has extensively studied the optimal composition of 
chemotherapy regimens for the treatment of ovarian cancer, both for the first- and second-line treatment. 
While there has been no general agreement on the optimal composition of the regimens, the beneficial effects 
(e.g. overall survival or progression free survival) of platinum agents (i.e. cisplatin or carboplatin) in the 
treatment of ovarian cancer have been demonstrated, e.g. [25,28]. In its technology appraisal 91, the National 
Institute for Health and Clinical Excellence (NICE) concludes that there is a significant increase in both the 
medium survival and medium progression free survival, when the patients undergo either a platinum (cisplatin 
or carboplatin) monotherapy or a paclitaxel-platinum combination therapy (as a first-line chemotherapy) [29]. 
Moreover, in the same technology appraisal the combination of a platinum-based compound with paclitaxel 
has been proposed as the recommended option for second-line treatment of women with (partially) platinum-
sensitive advanced ovarian cancer. Furthermore, the “Bristol-Myers Squibb” model estimates that the use of a 
paclitaxel-platinum treatment could result in a gain of 1.73 life-years, compared to a gain of 1.27 years for 
single-agent paclitaxel [30]. We were unable to find any events related to the administration of a platinum 
agent in the context of a chemotherapy treatment for ovarian cancer. Neither did the event log contain the 
trade names “Platinol” (for cisplatin) and/or “Paraplatin” (for carboplatin).  
Secondly, the in-depth investigation of the activity sequences of the patients with ovarian cancer that 
received a paclitaxel based chemotherapy uncovered two important deviations. The activity log did not 
contain a surgery for 2 out of the 3 patients that were diagnosed with ovarian cancer stage Ia, while this is 
advised in [23]. In addition, while patients diagnosed with ovarian cancer stage Ic and stage II have an 
estimated disease recurrence rate between 25-40% and therefore require postoperative paclitaxel 
chemotherapy, we did not find any patient that received this type chemotherapy. 
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Additionally, the NICE Guidance TA108 estimates the cost per patient at approximately £4000 for an 
average of four cycles of treatment. Based on the assumption that one case describes the full treatment of an 
individual person, we conclude that this event log has an average of approximately 7 treatment cycles and 
conclude that for only 30% of the patients 4 cycles or less was adequate, see Figure 3. Further research must 
be performed in order to determine what caused the high deviation of the real number of treatment cycles 
compared to the prescribed number of treatment cycles. 
 
 .  
Figure 3: Distribution and cumulative distribution of the number of treatment cycles per patient 
4.3.  Limitations 
The limitations of the current study can be grouped in two categories: the limitations of the constructed 
event log and the local hospital conditions. The event log inherently suffered from the following limitations: a 
limited accuracy of the timestamps making performance analyses irrelevant and coarsely recorded additional 
event information (e.g. the originator information consisted of high-level departmental information). 
Moreover, we cannot guarantee that the log with a limited time frame covers all the activities of all the 
patients. The data is retrieved from a financial information system and consequently might not cover all the 
(non-invoiced) activities in the actual process. Secondly, the event log that was used in this care process 
analysis study was supplied by a university hospital, which is an important local condition as the log may 
contain a disproportionate amount of special and/or high risk cases. These limitations, however, do not affect 
the potential of applying process mining techniques for the continuous quality and performance monitoring of 
the care processes. 
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